Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
Status:
Not yet recruiting
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
This is a prospective phase II multi-center trial of the combination of the PARP inhibitor
olaparib with the immune checkpoint inhibitor pembrolizumab in advanced uveal melanoma.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute